Literature DB >> 22460757

Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation.

B K Arendt1, D K Walters, X Wu, R C Tschumper, P M Huddleston, K J Henderson, A Dispenzieri, D F Jelinek.   

Abstract

Multiple myeloma (MM) is preceded by the asymptomatic pre-malignant state, monoclonal gammopathy of undetermined significance (MGUS). Although MGUS patients may remain stable for years, they are at increased risk of progressing to MM. A better understanding of the relevant molecular changes underlying the transition from an asymptomatic to symptomatic disease state is urgently needed. Our studies show for the first time that the CD147 molecule (extracellular matrix metalloproteinase inducer) may be having an important biological role in MM. We first demonstrate that CD147 is overexpressed in MM plasma cells (PCs) vs normal and pre-malignant PCs. Next, functional studies revealed that the natural CD147 ligand, cyclophilin B, stimulates MM cell growth. Moreover, when MM patient PCs displaying bimodal CD147 expression were separated into CD147(bright) and CD147(dim) populations and analyzed for proliferation potential, we discovered that CD147(bright) PCs displayed significantly higher levels of cell proliferation than did CD147(dim) PCs. Lastly, CD147-silencing significantly attenuated MM cell proliferation. Taken together, these data suggest that the CD147 molecule has a key role in MM cell proliferation and may serve as an attractive target for reducing the proliferative compartment of this disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22460757      PMCID: PMC3915875          DOI: 10.1038/leu.2012.91

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  53 in total

Review 1.  A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death.

Authors:  D P Steensma; M A Gertz; P R Greipp; R A Kyle; M Q Lacy; J A Lust; J R Offord; M F Plevak; T M Therneau; T E Witzig
Journal:  Blood       Date:  2001-04-15       Impact factor: 22.113

2.  CD147 is a signaling receptor for cyclophilin B.

Authors:  V Yurchenko; M O'Connor; W W Dai; H Guo; B Toole; B Sherry; M Bukrinsky
Journal:  Biochem Biophys Res Commun       Date:  2001-11-09       Impact factor: 3.575

3.  The effectiveness of double-stranded short inhibitory RNAs (siRNAs) may depend on the method of transfection.

Authors:  D K Walters; D F Jelinek
Journal:  Antisense Nucleic Acid Drug Dev       Date:  2002-12

4.  Expression of the extracellular matrix metalloproteinase inducer (EMMPRIN) and the matrix metalloproteinase-2 in bronchopulmonary and breast lesions.

Authors:  S Caudroy; M Polette; J M Tournier; H Burlet; B Toole; S Zucker; P Birembaut
Journal:  J Histochem Cytochem       Date:  1999-12       Impact factor: 2.479

5.  Interaction with glycosaminoglycans is required for cyclophilin B to trigger integrin-mediated adhesion of peripheral blood T lymphocytes to extracellular matrix.

Authors:  Fabrice Allain; Christophe Vanpouille; Mathieu Carpentier; Marie-Christine Slomianny; Sandrine Durieux; Geneviève Spik
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

6.  Active site residues of cyclophilin A are crucial for its signaling activity via CD147.

Authors:  Vyacheslav Yurchenko; Gabriele Zybarth; Matthew O'Connor; Wei Wei Dai; Giovanni Franchin; Tang Hao; Huiming Guo; Hsiu-Cheng Hung; Bryan Toole; Philippe Gallay; Barbara Sherry; Michael Bukrinsky
Journal:  J Biol Chem       Date:  2002-04-09       Impact factor: 5.157

7.  Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions.

Authors:  J Sun; M E Hemler
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

8.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

9.  Immunophenotypic and genotypic characterisation of multiple myelomas with adverse prognosis characterised by immunohistological expression of the T cell related antigen CD45RO (UCHL-1).

Authors:  D M Menke; H P Horny; H Griesser; E J Atkinson; E Kaiserling; R A Kyle
Journal:  J Clin Pathol       Date:  1998-06       Impact factor: 3.411

10.  Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.

Authors:  S Vincent Rajkumar; Ruben A Mesa; Rafael Fonseca; Georgene Schroeder; Matthew F Plevak; Angela Dispenzieri; Martha Q Lacy; John A Lust; Thomas E Witzig; Morie A Gertz; Robert A Kyle; Stephen J Russell; Philip R Greipp
Journal:  Clin Cancer Res       Date:  2002-07       Impact factor: 12.531

View more
  17 in total

1.  Tumor-associated macrophages and extracellular matrix metalloproteinase inducer in prognosis of multiple myeloma.

Authors:  S Panchabhai; K Kelemen; G Ahmann; S Sebastian; J Mantei; R Fonseca
Journal:  Leukemia       Date:  2015-07-23       Impact factor: 11.528

2.  CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells.

Authors:  Denise K Walters; Bonnie K Arendt; Diane F Jelinek
Journal:  Cell Cycle       Date:  2013-09-03       Impact factor: 4.534

3.  Eosinophils regulate peripheral B cell numbers in both mice and humans.

Authors:  Tina W Wong; Alfred D Doyle; James J Lee; Diane F Jelinek
Journal:  J Immunol       Date:  2014-03-10       Impact factor: 5.422

4.  OWL-NETS: Transforming OWL Representations for Improved Network Inference.

Authors:  Tiffany J Callahan; William A Baumgartner; Michael Bada; Adrianne L Stefanski; Ignacio Tripodi; Elizabeth K White; Lawrence E Hunter
Journal:  Pac Symp Biocomput       Date:  2018

5.  Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.

Authors:  Ruth Eichner; Michael Heider; Vanesa Fernández-Sáiz; Frauke van Bebber; Anne-Kathrin Garz; Simone Lemeer; Martina Rudelius; Bianca-Sabrina Targosz; Laura Jacobs; Anna-Maria Knorn; Jolanta Slawska; Uwe Platzbecker; Ulrich Germing; Christian Langer; Stefan Knop; Herrmann Einsele; Christian Peschel; Christian Haass; Ulrich Keller; Bettina Schmid; Katharina S Götze; Bernhard Kuster; Florian Bassermann
Journal:  Nat Med       Date:  2016-06-13       Impact factor: 53.440

6.  The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells.

Authors:  Di Zhu; Zhongqiu Wang; Jian-Jun Zhao; Teresa Calimeri; Jiang Meng; Teru Hideshima; Mariateresa Fulciniti; Yue Kang; Scott B Ficarro; Yu-Tzu Tai; Zachary Hunter; Douglas McMilin; Haoxuan Tong; Constantine S Mitsiades; Catherine J Wu; Steven P Treon; David M Dorfman; Geraldine Pinkus; Nikhil C Munshi; Pierfrancesco Tassone; Jarrod A Marto; Kenneth C Anderson; Ruben D Carrasco
Journal:  Nat Med       Date:  2015-05-25       Impact factor: 53.440

7.  Multiple myeloma dell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation.

Authors:  Bonnie K Arendt; Denise K Walters; Xiaosheng Wu; Renee C Tschumper; Diane F Jelinek
Journal:  Oncotarget       Date:  2014-07-30

8.  TRAF6 regulates melanoma invasion and metastasis through ubiquitination of Basigin.

Authors:  Zhongling Luo; Xu Zhang; Weiqi Zeng; Juan Su; Keda Yang; Lixia Lu; Chuan Bian Lim; Wen Tang; Lisha Wu; Shuang Zhao; Xuekun Jia; Cong Peng; Xiang Chen
Journal:  Oncotarget       Date:  2016-02-09

9.  Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation.

Authors:  Derek James Hanson; Shingen Nakamura; Ryota Amachi; Masahiro Hiasa; Asuka Oda; Daisuke Tsuji; Kohji Itoh; Takeshi Harada; Kazuki Horikawa; Jumpei Teramachi; Hirokazu Miki; Toshio Matsumoto; Masahiro Abe
Journal:  Oncotarget       Date:  2015-10-20

Review 10.  How, with whom and when: an overview of CD147-mediated regulatory networks influencing matrix metalloproteinase activity.

Authors:  G Daniel Grass; Bryan P Toole
Journal:  Biosci Rep       Date:  2015-11-24       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.